- Home
- EXAS vs DOCS Comparison
EXAS vs DOCS Comparison
Compare EXAS & DOCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXAS
- DOCS
- Stock Information
- Founded
- EXAS 1995
- DOCS 2010
- Country
- EXAS United States
- DOCS United States
- Employees
- EXAS N/A
- DOCS N/A
- Industry
- EXAS Medical Specialities
- DOCS Retail: Computer Software & Peripheral Equipment
- Sector
- EXAS Health Care
- DOCS Technology
- Exchange
- EXAS Nasdaq
- DOCS Nasdaq
- Market Cap
- EXAS 11.6B
- DOCS 9.9B
- IPO Year
- EXAS N/A
- DOCS 2021
- Fundamental
- Price
- EXAS $59.30
- DOCS $53.85
- Analyst Decision
- EXAS Strong Buy
- DOCS Hold
- Analyst Count
- EXAS 16
- DOCS 15
- Target Price
- EXAS $72.80
- DOCS $51.93
- AVG Volume (30 Days)
- EXAS 2.2M
- DOCS 1.8M
- Earning Date
- EXAS 11-05-2024
- DOCS 02-06-2025
- Dividend Yield
- EXAS N/A
- DOCS N/A
- EPS Growth
- EXAS N/A
- DOCS 50.58
- EPS
- EXAS N/A
- DOCS 0.87
- Revenue
- EXAS $2,692,328,000.00
- DOCS $516,849,000.00
- Revenue This Year
- EXAS $11.81
- DOCS $16.37
- Revenue Next Year
- EXAS $11.41
- DOCS $9.56
- P/E Ratio
- EXAS N/A
- DOCS $60.30
- Revenue Growth
- EXAS 11.91
- DOCS 15.29
- 52 Week Low
- EXAS $40.62
- DOCS $22.96
- 52 Week High
- EXAS $79.62
- DOCS $61.75
- Technical
- Relative Strength Index (RSI)
- EXAS 48.86
- DOCS 56.48
- Support Level
- EXAS $61.28
- DOCS $50.96
- Resistance Level
- EXAS $62.15
- DOCS $53.88
- Average True Range (ATR)
- EXAS 2.02
- DOCS 1.71
- MACD
- EXAS 0.15
- DOCS -0.39
- Stochastic Oscillator
- EXAS 3.39
- DOCS 43.50
About EXAS Exact Sciences Corporation
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a precancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
About DOCS Doximity Inc.
Doximity Inc is a digital platform for U.S. medical professionals. Its cloud-based platform provides members with tools specifically built for medical professionals, enabling them to collaborate with their colleagues, securely coordinate patient care, conduct virtual patient visits, stay up-to-date with the latest medical news and research, and manage their careers.